To further investigate whether STAG2 mutations may be preferentially acquired at MDS stage and lead to development of secondary AML, we extracted all patients with available longitudinal mutation data and identified 23 patients diagnosed with STAG2-mutant AML with at least one mutational assessment before AML diagnosis. This evidence concerns the gene STAG2 and myelodysplastic syndrome.